Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Merck Sharp & Dohme LLC
Georgetown University
Peking Union Medical College Hospital
Hoosier Cancer Research Network
National Institutes of Health Clinical Center (CC)